NCT07167797View on ClinicalTrials.gov

Evaluation of the Role of Vitamin D in Reducing the Severity and Duration of Rotavirus Infection in Iraqi Children

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

May 1, 2025

Study Completion Date

November 6, 2025

Conditions
Rotaviral Gastroenteritis
Interventions
DIETARY_SUPPLEMENT

Vitamin D (Cholecalciferol )

Group II (Treatment) group: received vitamin D single oral dose 300000 IU for age \< 1 year and dose of 600000IU for age\> 1 year in addition to standard treatment

DRUG

Standard treatment for rotavirus

Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion

Trial Locations (1)

00964

AL Kadhimia pediatric hospital, Baghdad

All Listed Sponsors
lead

University of Baghdad

OTHER

NCT07167797 - Evaluation of the Role of Vitamin D in Reducing the Severity and Duration of Rotavirus Infection in Iraqi Children | Biotech Hunter | Biotech Hunter